Holen Sie sich die Stockscreener-App
10.95
16.09%
-2.1278
Evommune Inc Aktie (EVMN) Neueste Nachrichten
Evommune Drops AD Program Following Phase 2B Trial Failure - The Dermatology Digest
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Canada
Evommune Reports EVO756 Phase 2b Trial Failure in Atopic Dermatitis, Halts Development for This Indication - Kalkine Media
Evommune (NYSE:EVMN) Price Target Lowered to $21.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Canada
Why is Evommune stock plunging today? By Investing.com - Investing.com Australia
RBC cuts Evommune stock price target on drug trial setback - Investing.com
Evommune's (EVMN) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Evommune stock maintains Buy rating despite trial setback By Investing.com - Investing.com Canada
Evommune stock maintains Buy rating despite trial setback - Investing.com
Evommune Halts Atopic Dermatitis Program Following Trial Failure - Benzinga
Why is Evommune stock sliding 13% today? - Investing.com
RBC Cuts Price Target on Evommune to $21 From $29, Keeps Outperform, Speculative Risk - marketscreener.com
Why is Evommune stock sliding 13% today? By Investing.com - Investing.com Canada
Why is Evommune stock tumbling today? By Investing.com - Investing.com Canada
Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss - allsci.com
Why Is EVMN Stock Down 13% After-Hours? - Yahoo Finance
Evommune scraps eczema drug after trial miss, shares plunge - marketscreener.com
Why is Evommune stock plunging today? - Investing.com
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis By Investing.com - Investing.com Canada
Evommune stock tumbles after trial misses primary endpoint - Investing.com
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis - Investing.com India
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis - Yahoo Finance Singapore
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Evommune (NYSE:EVMN) Coverage Initiated at Needham & Company LLC - MarketBeat
Evommune (EVMN) Financial Update: EPS Misses Its Estimate in Latest Trading; Trading Move: Shares Move 10.63% Down in Latest TradingProfit Margin Analysis - vinanet.vn
Evommune (NYSE:EVMN) Trading Down 6.9%Here's What Happened - MarketBeat
Evommune Inc (EVMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evommune Inc. (EVMN) Rises 4.12% to $14.65 as Clinical-Stage Biotech Draws Fresh InterestHull Moving Average - vinanet.vn
Evommune (EVMN) Slips 0.42% to $14.06 as Consolidation Tightens Around Key SupportBreakout Stock Alerts - vinanet.vn
HC Wainwright Issues Negative Estimate for Evommune Earnings - MarketBeat
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Evommune Inc. (EVMN) Holds Steady at $14.07 as Consolidation ContinuesBearish Sentiment - dars.gov.et
Analysts Conflicted on These NA Names: Bob’s Discount Furniture, Inc. (BOBS), Evommune, Inc. (EVMN) and Once Upon a Farm, PBC (OFRM) - The Globe and Mail
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Evommune (NYSE:EVMN) Price Target Cut to $29.00 by Analysts at Royal Bank Of Canada - MarketBeat
Evommune, Inc. Stock 12‑Month Price Target Cut to $30.11, Implies 125% Upside - TradingView
Evommune Inc (EVMN) Stock News Today - TradingKey
RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Evommune Inc (EVMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EVMN: Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum - TradingView
EVMN: Strong cash reserves support key clinical milestones despite higher losses and no Q2 revenue - TradingView
Evommune reports Q2 2026 net loss of $32.2M, cash $288.0M; EVO756 Phase 2b AD readout due Sept 2026 - TradingView
Evommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary - TradingView
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial - Streetwise Reports
Evommune Inc. (EVMN) Advances 2.76% as Shares Test Key Resistance Near $14Low Vol Factor - dars.gov.et
Evommune Inc. (EVMN) Holds Near $13.09 as Biotech Stock Consolidates Between Key LevelsUpthrust Pattern - dars.gov.et
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX) - The Globe and Mail
896,700 Shares in Evommune, Inc. $EVMN Purchased by Janus Henderson Group PLC - MarketBeat
HC Wainwright Reiterates Neutral Rating for Evommune (NYSE:EVMN) - MarketBeat
Evommune stock: H.C. Wainwright reiterates Neutral rating By Investing.com - Investing.com India
Evommune stock: H.C. Wainwright reiterates Neutral rating - Investing.com
EVMN Q1 2026 Earnings: Narrower Loss Beats Estimates by 15.6% Amid No RevenuePre-Earnings Drift - vinanet.vn
Evommune doses first patient in migraine prevention trial By Investing.com - Investing.com Nigeria
Evommune doses first patient in migraine prevention trial - Investing.com
EVMN Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline AdvancesRevenue Beat Analysis - vinanet.vn
Evommune Inc (EVMN) Institutional Confidence - TradingKey
0.28%
4.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):